Background Systemic-onset juvenile idiopathic arthritis does not always respond to available
treatments, including antitumour necrosis factor agents. We investigated the efficacy and …

Objective. Rapidly progressive interstitial lung disease (RP-ILD) is a rare but potentially fatal
complication of JDM. The aim of this study was to establish markers for the prediction and …

<p>Familial cold autoinflammatory syndrome, Muckle-Wells syndrome (MWS), and chronic,
infantile, neurological, cutaneous and articular (CINCA) syndrome are dominantly inherited …

Background Juvenile idiopathic arthritis can be refractory to some or all treatment regimens,
therefore new medications are needed to treat this population. This trial assessed the …

Objective. To assess the longterm safety and effectiveness of tocilizumab (TCZ) in systemic-onset
juvenile idiopathic arthritis (sJIA). Methods. The longterm extension phase of 2 pivotal …

The objective of this study was to evaluate the efficacy, pharmacokinetics, and safety of
adalimumab in patients with polyarticular juvenile idiopathic arthritis (JIA) in Japan. Patients …

Background Deficiency of adenosine deaminase 2 (DADA2) is an autosomal recessive
inflammatory disease caused by loss-of-function mutations in both alleles of the ADA2 gene. …

Juvenile idiopathic arthritis (JIA) is the most common disease in pediatric rheumatism.
There is no specific symptom or examination finding for JIA, and the diagnosis is made by …

Background This study aimed to determine the influence of tocilizumab (TCZ) in modifying
the clinical and laboratory features of macrophage activation syndrome (MAS) complicating …

Background Although there are many reports on Juvenile Idiopathic arthritis-associated uveitis
(JIA-U) from various countries, especially from Europe and North America, there are few …